Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.75 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.75 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.75 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.75 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.75 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.75 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.75 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.65 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6865490 | 0.93 | OPRD1 (0.81) | OPRM1OPRK1MRGPRX2OPRD1ADRB1 | |
| SCHEMBL6865494 | 0.93 | OPRD1 (0.81) | OPRM1OPRK1MRGPRX2OPRD1ADRB1 | |
| SCHEMBL4545443 | 0.90 | OPRM1 (0.68) | OPRM1OPRK1MRGPRX2OPRD1ADRB1 | |
| SCHEMBL11503572 | 0.88 | OPRD1 (0.78) | OPRM1OPRK1MRGPRX2OPRD1ADRB1 | |
| SCHEMBL10537816 | 0.88 | OPRD1 (0.78) | OPRM1OPRK1MRGPRX2OPRD1ADRB1 | |
| SCHEMBL25330324 | 0.88 | OPRD1 (0.78) | OPRM1OPRK1MRGPRX2OPRD1ADRB1 | |
| Ethylmorphine SCHEMBL16922138 | 0.87 | OPRD1 (0.80) | OPRM1OPRK1MRGPRX2OPRD1ADRB1 | |
| Ethylmorphine SCHEMBL14611951 | 0.87 | OPRD1 (0.80) | OPRM1OPRK1MRGPRX2OPRD1ADRB1 | |
| Ethylmorphine SCHEMBL14516212 | 0.87 | OPRD1 (0.80) | OPRM1OPRK1MRGPRX2OPRD1ADRB1 | |
| Ethylmorphine SCHEMBL15757784 | 0.87 | OPRD1 (0.80) | OPRM1OPRK1MRGPRX2OPRD1ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190247388-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2019-08-15 | — | — | US | disclosed |
| US-10307416-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190046523-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2019-02-14 | — | — | US | disclosed |
| US-9925182-B2 | Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound | NEKTAR THERAPEUTICS (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925182-B2 | Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound | NEKTAR THERAPEUTICS (US) | 2018-03-27 | — | — | US | disclosed |
| US-9827239-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2017-11-28 | — | — | US | disclosed |
| US-9827239-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170112826-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2017-04-27 | — | — | US | disclosed |
| US-20170112826-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2017-04-27 | — | — | US | disclosed |
| US-20170079975-A1 | Compositions, Dosage Forms, and Co-Administration of an Opioid Agonist Compound and an Analgesic Compound | NEKTAR THERAPEUTICS | 2017-03-23 | — | — | US | disclosed |
| US-20120264775-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264775-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120184581-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184581-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2012-07-19 | — | — | US | disclosed |
| US-8173666-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173666-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110237614-A1 | Pegylated Opioids with Low Potential for Abuse | NEKTAR THERAPEUTICS (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237614-A1 | Pegylated Opioids with Low Potential for Abuse | NEKTAR THERAPEUTICS (US) | 2011-09-29 | — | — | US | disclosed |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112826-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRK1 3/4885MRGPRX2 311/4885 |
| US-10307416-B2 | Oligomer-opioid agonist conjugates | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRK1 3/4885MRGPRX2 311/4885 |
| US-20170079975-A1 | Compositions, Dosage Forms, and Co-Administration of an Opioid Agonist Compound and an Analgesic Compound | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRK1 3/4885MRGPRX2 69/4885 |
| US-20190046523-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRK1 3/4885MRGPRX2 311/4885 |
| US-20110237614-A1 | Pegylated Opioids with Low Potential for Abuse | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRK1 3/4885MRGPRX2 509/4885 |
| US-20190247388-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRK1 3/4885MRGPRX2 311/4885 |
| US-20120184581-A1 | Oligomer-Opioid Agonist Conjugates | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRK1 3/4885MRGPRX2 311/4885 |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRK1 3/4885MRGPRX2 311/4885 |
| US-20120264775-A1 | Oligomer-Opioid Agonist Conjugates | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRK1 3/4885MRGPRX2 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.